Conference Proceedings
Single-Agent Ibrutinib Vs Chemoimmunotherapy Regimens for Treatment-Naive Patients with Chronic Lymphocytic Leukemia (CLL): A Cross-Trial Comparison
Tadeusz Robak, Jan A Burger, Alessandra Tedeschi, Paul M Barr, Carolyn Jane Owen, Osnat Bairey, Peter Hillmen, David Simpson, Sebastian Grosicki, Stephen Devereux, Helen McCarthy, Steven Coutre, Quach Hang, Gianluca Gaidano, Zvenyslava Maslyak, Don A Stevens, Carol Moreno, Devinder Gill, Ian W Flinn, John Gribben Show all
BLOOD | AMER SOC HEMATOLOGY | Published : 2017
Grants
Funding Acknowledgements
Robak: Pharmacyclics LLC, an AbbVie Company: Research Funding; AbbVie: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Akari Therapeutics Plc: Research Funding. Burger: TG Therapeutics: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; Novartis: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses; Pharmacyclics LLC, an AbbVie Company: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; Janssen: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses; Gilead: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding. Tedeschi: Janssen: Consultancy, Other: travel expenses; Gilead: Consultancy, Other: travel expenses; AbbVie: Consultancy. Barr: Novartis: Consultancy; Pharmacyclics LLC, an AbbVie Company: Consultancy, Research Funding; Seattle Genetics: Consultancy; Gilead: Consultancy; Infinity: Consultancy; Celgene: Consultancy; AbbVie: Consultancy, Research Funding. Owen: Gilead: Honoraria, Research Funding. Owen: Gilead: Honoraria, Research Funding; Janssen: Honoraria; AbbVie: Honoraria; Celgene: Honoraria; AstraZeneca: Honoraria; Pharmacyclics LLC, an AbbVie Company: Research Funding; Lundbeck: Honoraria; Roche: Consultancy, Honoraria, Research Funding. Bairey: Janssen: Consultancy, Research Funding. Hillmen: Novartis: Honoraria, Research Funding; AbbVie: Consultancy, Honoraria, Research Funding; Roche: Consultancy, Honoraria, Research Funding; Alexion Pharmaceuticals, Inc.: Consultancy, Honoraria; GSK: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Gilead: Consultancy, Honoraria, Research Funding; Pharmacyclics LLC, an AbbVie Company: Honoraria, Research Funding; Celgene: Research Funding. Simpson: Amgen: Research Funding; Onyx: Research Funding; Roche: Honoraria; Pharmacyclics LLC, an AbbVie Company: Research Funding; Celgene: Honoraria, Other: travel expenses. Devereux: Roche: Consultancy, Other: travel expenses; GSK: Consultancy; MSD: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; Servier: Other: Advisory board; Gilead: Consultancy, Honoraria, Other: travel expenses, Speakers Bureau; Janssen: Consultancy, Honoraria, Other: travel expenses, Speakers Bureau. McCarthy: Chugai: Other: travel expenses; Celgene: Other: travel expenses; Roche: Consultancy, Other: travel expenses; Janssen: Consultancy, Honoraria, Other: travel expenses; Novartis: Honoraria, Other: travel expenses; AbbVie: Honoraria, Other: travel expenses. Coutre: AbbVie: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; Janssen: Consultancy; Pharmacyclics LLC, an AbbVie Company: Consultancy, Research Funding; Gilead: Consultancy, Research Funding. Quach: Amgen: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria; Takeda: Consultancy, Honoraria. Gaidano: Gilead: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; Roche: Consultancy, Honoraria; Janssen: Consultancy, Honoraria. Moreno: Gilead: Consultancy, Research Funding; Janssen: Consultancy. Gill: Janssen: Consultancy, Honoraria, Other: travel expenses.Flinn: Pharmacyclics: Research Funding; Pfizer: Research Funding; Forty Seven: Research Funding; Merck: Research Funding; Takeda: Research Funding; Infinity: Research Funding; Acerta: Research Funding; Gilead: Research Funding; TG Therapeutics: Research Funding; Calithera: Research Funding; Portola: Research Funding; Incyte: Research Funding; Pharmacyclics LLC: Research Funding; AbbVie Company: Research Funding; Trillium: Research Funding; Genentech: Research Funding; Janssen: Research Funding; Curis: Research Funding; KITE: Research Funding; Constellation: Research Funding; Verastem: Research Funding; Beigene: Research Funding; Seattle Genetics: Research Funding; Janssen: Research Funding; Celgene: Research Funding; Novartis: Research Funding; Agios: Research Funding. Gribben: Gilead: Other: travel expenses; Acerta: Research Funding; Janssen: Research Funding; Celgene: Consultancy; Unum: Consultancy. Mokatrin: Pharmacyclics LLC, an AbbVie Company: Employment; AbbVie: Equity Ownership. Cheng: Pharmacyclics LLC, an AbbVie Company: Employment; AbbVie: Equity Ownership; Johnson & Johnson: Equity Ownership. Styles: AbbVie: Equity Ownership; Pharmacyclics LLC, an AbbVie Company: Employment. James: Pharmacyclics LLC, an AbbVie Company: Employment; AbbVie: Equity Ownership. Kipps: Genentech: Consultancy, Research Funding; Gilead: Consultancy, Speakers Bureau; Pharmacyclics LLC, an AbbVie Company: Consultancy, Honoraria, Research Funding; Oncternal: Research Funding; Celgene: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria, Research Funding; Roche: Consultancy, Honoraria. Ghia: Pharmacyclics LLC, an AbbVie Company: Consultancy; Janssen: Consultancy, Research Funding; Gilead: Consultancy, Research Funding, Speakers Bureau; Adaptive: Consultancy; AbbVie: Consultancy; Roche: Consultancy; Novartis: Research Funding.